Full Press Release Details
Calliditas appoints Group General Counsel
Calliditas Therapeutics AB (publ) ("Calliditas")
today announced the appointment of Jonathan Schur as Group General Counsel, effective October 1, 2020.
Jonathan Schur has over 30 years of experience as a lawyer and
is a member of the New York and Paris Bars. His practice focuses on work for pharmaceutical companies at all stages of development,
from biotech companies advancing breakthrough technologies, to specialty and large pharmaceutical companies building commercial
franchises. Having practiced in Paris for most of his career, Jonathan bridges the gap between the US and European legal and regulatory
traditions. He advises companies on collaborations, product acquisitions, product distribution, the legal and regulatory aspects
of product and pricing authorizations, clinical trials, agreements with hospitals and physicians, marketing practices and privacy
Prior to joining Calliditas, Mr. Schur
was a Partner in the Life Sciences team at Goodwin Procter LLP, and before that a partner and co-managing partner of the Paris
Office of Dechert LLP. He is a graduate of Harvard College and Harvard Law School.
"As Calliditas grows its overall
footprint and advances its lead product candidate Nefecon towards registration and, if approved, commercialization, the importance
of an experienced in-house legal resource becomes increasingly critical. We are excited that Jonathan has agreed to join us and
help prepare Calliditas for its next stage of development," said Ren e Aguiar-Lucander, Chief Executive Officer.
"The Calliditas management team has
demonstrated its ability to identify products and technologies with significant potential and develop and implement approaches
that can maximize their chances of success. I am looking forward to helping Calliditas execute its ambitious and exciting strategy,"
said Jonathan Schur.
For further information, please contact:
Ren e Aguiar-Lucander, CEO, Calliditas
Mikael Widell, Communications and IR
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on August 25, 2020 at 08:00 a.m. CET.
Calliditas Therapeutics is a specialty pharmaceutical company
based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with
an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate,
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the
treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are
no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon
in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT).
Visit www.calliditas.com for further information.